PolyModels Hub raises GBP 1.1m
Complex therapeutic modalities require sophisticated drug processes to obtain molecules with the desired properties while maintaining high-quality standards. Historically, R&D expenditures per molecule have consistently increased. However, recent advancements in digital technology and data integration offer hope for reversing this trend, making the business model more sustainable.
The use of digital models in process design is a foundational paradigm driving the transformation in R&D. These models are progressively being adopted across the industry. Despite their potential, the adoption of these tools by small, medium, and even large pharma organizations remains limited due to the complexity involved in managing and understanding such advanced modeling tools. A major challenge faced by pharmaceutical organizations is selecting the appropriate modeling approach, especially when experimental data is limited or constrained, to address specific challenges during medicine development. Moreover, integrating models into the traditional drug development workflow is challenging despite the recent push and advocacy from major regulatory agencies.
This is where PolyModels Hub introduces ModelFlow, a comprehensive digital platform designed to revolutionise pharma process development. ModelFlow seamlessly integrates models, scientific data, and insights into a single, cohesive product. This platform shifts the focus to advancing a company's medicine portfolio through regulatory and business milestones by offering a robust solution for project management and the maximisation of digital tools.
With ModelFlow, scientists, digital teams, and pharma leaders can collaborate effectively, building and managing every aspect of how models should create significant impact and value in developing new drugs or optimising existing ones. By leveraging the founders' combined expertise, ModelFlow delivers a streamlined tech-enabled library of model-based workflows that unites essential data, information, model files, web-app deployment and insights into an exceptionally simple yet highly effective tool.
“Developing a drug remains an expensive and time-consuming process. Unlike other industries, product development in pharmaceuticals relies heavily on numerous experiments with minimal knowledge transfer from past products, driven by the expertise and know-how of scientists. We have witnessed first-hand the inefficiencies of traditional drug development, as well as the growing desire and business need to transform this field. Our vision for PolyModels Hub is to revolutionise how scientists, digital teams, and senior stakeholders collaborate to accelerate development efforts and bring breakthrough therapies to market faster than ever. With today's advanced technology, supportive business context, and favourable regulatory framework, we believe now is the perfect time to realise this vision,” said Antonio Benedetti, CEO, PolyModels Hub.
Harry Christodoulou, CSO, PolyModels Hub added: "Modeling and simulations in the pharmaceutical industry are becoming increasingly popular, with entire teams now focusing on digitalizing their processes using advanced techniques, ranging from AI to Computational Fluid Dynamics. These digital solutions require a unique central platform where they can create tangible value for scientific and modeling projects in a systematic manner. This is precisely why we founded PolyModels Hub and developed our product, ModelFlow.”
“Our next steps involve significantly enhancing our platform, rolling out advanced modeling and simulation tools, integrating the best software and technology components into a simple and intuitive platform. Additionally, our AI layer will recommend the optimal tools for each task, ensuring efficiency and precision. We are also committed to expanding our team with top-tier talent to support our ambitious goals and drive the digital transformation in pharma process development," said Antonio Yankey, CTO, PolyModels Hub.
“The pharma industry is being revolutionised by modern technologies including AI, biotechnology, and robotics. Yet, pharma process development, which is a critical part of taking a drug product to market, is still driven by the empirical knowledge of scientists and relies on paper-based systems and manual processes. PolyModels Hub brings a rare mix of chemical and software engineering expertise to digitalise pharma process development and help pharma deliver breakthrough therapies faster to the growing and ageing population. We are excited to work together with the team towards bringing their vision forward”, added Alex Alexakis, Partner, Marathon Venture Capital.
About PolyModels Hub
PolyModels Hub is a pioneering team of pharma R&D and manufacturing specialists committed to accelerating the adoption of digital technologies in pharma process development. With expertise in chemical and software engineering, PolyModels Hub offers an innovative perspective and solution to the industry.
The company is on a journey to empower scientists with AI tools to model, simulate, and get access to insights across all steps and protocols followed to turn chemical compounds into safe drug products - all inside a collaborative platform made for pharma.
With PolyModels Hub's platform, pharmaceutical companies can deliver breakthrough therapies to patients faster, putting emphasis on how modeling can aid the development of robust processes while drug's quality control, delivering the desired result consistently across batches and providing assurance to regulatory authorities that the drug can be reliably produced to meet stringent standards.
About Marathon Venture Capital
Marathon Venture Capital is a seed-stage venture capital fund helping ambitious founders build world-class technology companies. With over €100 million in capital raised, Marathon is the first investor in fast-growing startups such as Causaly, Learnworlds, and Hack The Box. To learn more, visit www.marathon.vc. For further information, please contact alex@marathon.vc
